Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun;34(3):e14376.
doi: 10.1111/jsr.14376. Epub 2024 Oct 26.

Patient experiences of narcolepsy and idiopathic hypersomnia in the Nordics: a patient journey map

Märt Vesinurm  1   2 , Christina Dünweber  3 , Jesper Rimestad  4 , Anne-Marie Landtblom  5   6 , Poul Jørgen Jennum  7
Affiliations

Patient experiences of narcolepsy and idiopathic hypersomnia in the Nordics: a patient journey map

Märt Vesinurm et al. J Sleep Res. 2025 Jun.

Abstract

Central disorders of hypersomnolence (CDH) are chronic diseases that significantly impact the lives of affected individuals. We aimed to explore the perspectives of individuals with narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH), and the challenges they encounter in their daily lives and within the healthcare systems in the Nordics. Interviews with patients (N = 41) and healthcare professionals (n = 14) and a patient survey (n = 70) were conducted in 2022 in Denmark, Sweden, Finland, and Norway to develop a patient journey map that visualises the patient with CDH journey and provides insights into the difficulties faced by these individuals. The patient journey mapping approach was chosen to focus on the processes and experiences of patients, highlighting the challenges they confront. Our findings revealed that the process of receiving a CDH diagnosis, as well as subsequent misdiagnoses and treatment, can be protracted and burdensome. CDH diagnoses remain poorly understood by neurologists, general practitioners, and the public, resulting in adverse consequences, with patients reporting a mean (standard deviation [SD]) time from symptom onset to diagnosis of 8.4 (5.11) years and a mean (SD) of 5.5 (4.17) productive hours lost/day. The available non-pharmaceutical support for patients with CDH, encompassing medical, psychological, educational, and professional assistance, was insufficient. The generalisability of the findings to one specific diagnosis is limited due to the collective analysis of the CDH. These findings are invaluable for identifying disruptions in the patient with CDH journeys and for designing improved pathways for those with NT1, NT2, and IH in the future.

Keywords: central disorders of hypersomnolence; idiopathic hypersomnia; lived experience; living with narcolepsy; patient experience; patient journey.

PubMed Disclaimer

Conflict of interest statement

The authors declare the following conflicts of interest: Märt Vesinurm is employed by Nordic Healthcare Group Oy, Helsinki, Finland. Christina Dünweber is employed at Takeda Pharma Denmark A/S. Jesper Rimestad is employed at Takeda Pharma Norway A/S. Dr Anne‐Marie Landtblom reports personal fees from Takeda AB, Jazz Pharmaceuticals, and UCB, as well as a research grant from Aoporphan drugs. Dr Poul Jørgen Jennum reports personal fees from Takeda and an advisory board, Takeda 2021. Both Dr Anne‐Marie Landtblom and Dr Poul Jørgen Jennum disclosed reimbursement for their contributions to the interviews during the work on the Nordic narcolepsy patient journey mapping.

Figures

FIGURE 1
FIGURE 1
Visualisation of the data collection process.
FIGURE 2
FIGURE 2
Structure of the patient journey map of central disorders of hypersomnolence.
FIGURE 3
FIGURE 3
Self‐reported average sleep during daytime, average sleep during night‐time, and average productive hours lost per day due to condition (Source, CDH online survey, N = 70, more detailed numbers provided in Table 2). IH, idiopathic hypersomnia; NT1, narcolepsy type 1; NT2, narcolepsy type 2.
See this image and copyright information in PMC

References

    1. Acquavella, J. , Mehra, R. , Bron, M. , Suomi, J. M. H. , & Hess, G. P. (2020). Prevalence of narcolepsy and other sleep disorders and frequency of diagnostic tests from 2013–2016 in insured patients actively seeking care. Journal of Clinical Sleep Medicine, 16(8), 1255–1263. - PMC - PubMed
    1. Bargiotas, P. , Dietmann, A. , Haynes, A. G. , Kallweit, U. , Calle, M. G. , Schmidt, M. , Mathis, J. , & Bassetti, C. L. (2019). The Swiss Narcolepsy Scale (SNS) and its short form (sSNS) for the discrimination of narcolepsy in patients with hypersomnolence: a cohort study based on the Bern Sleep‐Wake Database. Journal of Neurology, 266(9), 2137–2143. 10.1007/s00415-019-09365-2 - DOI - PubMed
    1. Bassetti, C. L. , Kallweit, U. , Vignatelli, L. , Plazzi, G. , Lecendreux, M. , Baldin, E. , Dolenc‐Groselj, L. , Jennum, P. , Khatami, R. , Manconi, M. , Mayer, G. , Partinen, M. , Pollmächer, T. , Reading, P. , Santamaria, J. , Sonka, K. , Dauvilliers, Y. , & Lammers, G. J. (2021). European guideline and expert statements on the management of narcolepsy in adults and children. European Journal of Neurology, 28(9), 2815–2830. - PubMed
    1. Billiard, M. , & Sonka, K. (2016). Idiopathic hypersomnia. Sleep Medicine Reviews, 29, 23–33. - PubMed
    1. Bolin, K. , Berling, P. , Wasling, P. , Meinild, H. , Kjellberg, J. , & Jennum, P. (2017). The cost‐utility of sodium oxybate as narcolepsy treatment. Acta Neurologica Scandinavica, 136(6), 715–720. - PubMed

Publication types